Finasteride DHT Blocking and the Side Effects It Causes
How does finasteride work, and why does blocking DHT cause side effects?
Finasteride doesn't fight your hair loss at the follicle. It works one step upstream, switching off the enzyme that turns testosterone into its more aggressive cousin, and that's exactly why the benefit and the side effects come out of one single action. Every tissue carrying that enzyme feels the change, not just your scalp.
Finasteride blocks type II 5-alpha-reductase and lowers serum DHT by roughly seventy percent, and because that same enzyme serves the prostate, genital skin and parts of the brain, the side effects come from the identical mechanism that protects your hair.
What is 5-alpha-reductase and what job does it do in the body?
Your body doesn't crank up androgen activity by flooding your blood with more testosterone. It does it locally, by parking a converting enzyme in whichever tissue needs a louder signal. That one design decision is why a drug aimed at a single enzyme can reach your prostate, your skin and your hairline all at once.
| Criteria | Type I (SRD5A1) | Type II (SRD5A2) |
|---|---|---|
| Main locations | Sebaceous glands, non-genital skin, liver, brain | Prostate, epididymis, genital skin, hair follicles |
| When it switches on | Active from birth | Rises sharply at puberty |
| Finasteride potency | Weakly inhibited | About 100 times more strongly inhibited |
| Clue from people born without it | Not described | Small prostate, undervirilised at birth, no balding |
5-alpha-reductase runs one irreversible NADPH-dependent reaction that turns testosterone into DHT, a molecule that binds the androgen receptor two to five times more tightly and lets go about five times slower.
How does finasteride bind to the enzyme, and is that inhibition reversible?
Most drugs sit in a target and wash back out once blood levels fall. This one doesn't. The enzyme starts taking it apart, and in the process the drug welds itself into place, which is why it clears your bloodstream in hours while its effect runs on for weeks.
- The enzyme takes the bait: The 4-azasteroid skeleton looks enough like testosterone that the enzyme accepts it as substrate.
- The reaction begins: Reduction starts, turning the drug into a dihydrofinasteride intermediate inside the active site.
- The lock welds shut: That intermediate bonds covalently to the NADP cofactor already sitting there.
- The enzyme retires: The complex has a sub-nanomolar dissociation constant and a half-life in weeks, so that molecule never converts testosterone again.
- Recovery waits on new protein: Conversion capacity comes back only as your cells build fresh enzyme, not as the drug clears.
Finasteride is a mechanism-based inhibitor that permanently disables each enzyme molecule it reaches, which is why a single one milligram dose cuts serum DHT by about sixty-five percent within twenty-four hours despite a plasma half-life of only six to eight hours.
Why does finasteride target the type II enzyme rather than blocking both isoenzymes?
Hitting one isoenzyme instead of both wasn't a limitation anyone settled for, it was the design. It does set a hard ceiling on how much DHT you can strip out, and that ceiling shows up plainly the moment you line it up against a drug that blocks both.
| Criteria | Selective (type II only) | Dual (both isoenzymes) |
|---|---|---|
| Serum DHT reduction | About 70% | More than 90% |
| Hair count in head-to-head trials | Smaller gain | Larger gain |
| Elimination half-life | 6 to 8 hours | Measured in weeks |
| Time for an unwanted effect to clear | Short | Long |
Finasteride inhibits type II about a hundredfold more potently than type I, so serum DHT plateaus near a seventy percent reduction and the five milligram prostate dose suppresses barely more than the one milligram hair dose.
How much does finasteride actually lower DHT in the scalp compared with in the blood?
Blood is simply the easiest place to take a sample, but your scalp is where the drug has to earn its keep, and the two numbers aren't identical. The gap is small, and the more useful lesson sits underneath it: roughly a third of the original signal keeps reaching your follicles no matter what you do.
- Serum reduction: Roughly seventy percent below baseline, plateauing within about a week.
- Scalp tissue reduction: Roughly sixty to seventy percent, sampled by punch biopsy.
- Dose escalation: Five milligrams daily buys only a few percentage points more.
- Individual testing: No clinical assay reports follicle-level DHT, so response is judged on photographs.
Scalp tissue DHT falls by roughly sixty to seventy percent on one milligram daily against about seventy percent in serum, and raising the dose to five milligrams deepens that suppression by only a few percentage points.
What does DHT do inside a hair follicle that makes lowering it slow hair loss?
The cells that actually build your hair shaft don't listen to DHT at all. The receptors sit in the dermal papilla, the small control room at the base of the follicle, and DHT works by changing the orders that room sends out. Shrink the control room a little each cycle and the hair it commissions comes back thinner every time.
- Binding: DHT locks onto androgen receptors in the dermal papilla and the complex moves into the nucleus.
- Signal shift: The papilla releases less IGF-1 and more inhibitory TGF-beta and dickkopf-1, which interferes with Wnt signalling.
- Shortened anagen: A growth phase that should run two to six years gets cut shorter with each pass.
- Miniaturisation: The papilla shrinks, so every new shaft is finer and shorter until a terminal hair becomes vellus.
DHT drives miniaturisation through the dermal papilla rather than the hair shaft itself, so follicles still cycling can enlarge again over six to twelve months once local DHT drops, while follicles dormant for years generally can't restart.
Which other tissues depend on DHT, and what happens when the supply drops there?
This is the part worth understanding before you start rather than after. The side effect list isn't a random pile of complaints, it's a map of every tissue carrying the same type II enzyme your scalp does. Knowing what's on that map tells you what to actually watch for.
- Prostate: Gland volume falls about twenty percent at the prostate dose, and PSA roughly halves.
- Ejaculate volume: Prostate and seminal vesicles supply most of the fluid, and both shrink.
- Sexual function: DHT supports nitric oxide synthase and central desire pathways, though testosterone carries much of it.
- Breast tissue: Slightly more testosterone aromatises to estradiol with less androgenic tone opposing it.
In the pivotal one milligram trials decreased libido was reported by about one point eight percent of treated men against one point three percent on placebo, erectile difficulty by one point three against zero point seven, and reduced ejaculate volume by zero point eight against zero point four.
Why does blocking the conversion raise testosterone and estradiol, and does that matter?
Picture testosterone pulling up to a junction with several exits. Close the one marked DHT and the traffic doesn't vanish, it redistributes down the roads still open. That's why this drug rearranges your whole hormone profile instead of simply subtracting one hormone from it.
Serum testosterone rises by roughly ten to twenty percent and estradiol by ten to fifteen percent on one milligram daily while LH and FSH stay unchanged, which explains breast tenderness but only a narrow slice of the rest.
Which reported side effects have a clear DHT mechanism behind them and which do not?
Sorting these by how alarming they sound gets you nowhere useful. Sort them by how well anyone can actually explain them and the list splits into two groups that deserve very different amounts of confidence.
In the blinded pivotal trials about three point eight percent of treated men reported a sexual side effect against two point one percent on placebo, and men warned about those effects beforehand reported them at roughly three times the rate of men who weren't told.
How do brain neurosteroids fit in, given the same enzyme makes allopregnanolone?
The androgen story simply can't cover the mood, sleep and cognition complaints, and the reason sits in a detail most people skip past. This isn't an androgen enzyme, it's a steroid enzyme, and progesterone has to pass through it too.
- The pathway: Progesterone becomes dihydroprogesterone, then allopregnanolone, through the same enzyme.
- The effect: Allopregnanolone strongly amplifies GABA-A signalling, your brain's main inhibitory system.
- The human signal: Spinal fluid measured after stopping the drug shows reduced allopregnanolone.
- The complication: Your brain leans mainly on type I, which this drug barely touches.
Reduced allopregnanolone weakening GABA-A signalling is the leading hypothesis for the neuropsychiatric complaints, but it rests on small studies and on a type I isoenzyme finasteride inhibits about a hundredfold less potently, so it stays a hypothesis rather than an established cause.
How quickly do DHT levels and their effects return after the drug is stopped?
Three separate clocks start ticking the day you stop, and running them together is where nearly all the confusion comes from. Your hormones reset in days, your hair unwinds over months, and the symptom clock is the one nobody can set reliably.
Serum DHT returns to baseline within one to two weeks of the last dose while the hair benefit unwinds over roughly six to twelve months, returning the scalp to about where it would have been had treatment never started.
